Group purchasing organizations have an important purpose in healthcare, but there are some concerns, explained Martin Makary, MD, MPH, a surgical oncologist and chief of the Johns Hopkins Islet Transplant Center.
Group purchasing organizations have an important purpose in healthcare, but there are some concerns, explained Martin Makary, MD, MPH, a surgical oncologist and chief of the Johns Hopkins Islet Transplant Center.
Transcript
Why do hospitals use group purchasing organizations for getting medications, medical devices, and devices? What are some of the pros and cons or using these organizations?
I recently summarized what I believe to be the advantage and disadvantages of GPOs [Group Purchasing Organizations] in an article in JAMA, and in my research, I learned a couple of things. Number 1, GPOs serve an important purpose in healthcare. They save hospitals all of the legal and contracting work of going out there and writing contracts with hundreds of different vendors. Just like they would buy supplies from an Office Depot or Home Depot catalogue, similarly, GPOs make many products available.
Where I have significant concerns is in a pay-to-play fee system that GPOs have adopted through a loophole or an exemption that’s been passed into law of the Sherman Anti-Trust Act. That exemption to the Sherman Anti-Trust act allows them legally to demand fees from manufacturers and pharma companies to be listed in the catalogues or to have premium listing or even sometimes sole supplier listing in a catalogue. It’s generally anti-competitive, it’s not good for patients, and when the GPOs are sharing back some of the profits to the hospital who is left holding the bag? Those high costs that the manufacturers build into the price of the medication or device gets passed all the way through to the patient.
So, we have stories of individuals patients paying absurd amounts of money for a medication in a hospital setting that’s been around for a long time. How do you explain a sudden shortage of a certain medication that’s been around for 50 years? Sometimes it’s the sole supplier contracting that allows monopoly dominance in certain markets that allows that supply chain to get flimsy.
There are a lot of complex issues around GPOs. I don’t think GPOs are bad. I think they serve a valuable purpose in healthcare. But, I do personally and philosophically believe that we should get rid of kickbacks in GPO industry, which are called administrative fees, and we should get rid of kickbacks that are in the PBM [pharmacy benefit manager] world that are called rebates, and we should get rid of all kickbacks in healthcare.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More